PetMed Express, Inc. filings document the regulatory record for a Florida public company operating the PetMeds and PetCareRx pet pharmacy businesses. Annual and current reports disclose operating results, non-GAAP reconciliations, intangible-asset impairment matters involving the PCRX trade name, and the financial reporting issues reflected in Forms 12b-25 and Nasdaq continued-listing notices.
Other filings cover governance and capital-structure matters, including annual meeting voting results, director elections, executive compensation advisory votes, audit committee composition, amendments to the shareholder rights agreement, and modifications to security holder rights. The record also includes Form 8-K disclosures for material agreements, board appointments, results releases, and listing compliance communications.
PetMed Express (PETS) Form 4 filing: On 18 Jul 2025, 10% owner Silvercape Investments Ltd purchased 17,565 common shares at $3.23 each (≈$56.7 k). The move raises its directly held stake to 2,360,496 shares. No sales or derivative transactions were disclosed. While the add-on represents only ~0.7% of the owner’s position, continued buying from a >10% holder can signal confidence without materially altering the share count or control position.
PetMed Express Inc. (PETS) Form 4 filing reports that 10% owner Silvercape Investments Ltd purchased 2,817 common shares on 07 July 02 2025 at $3.22 per share, for an outlay of roughly $9.1 thousand. Following the transaction, Silvercape directly holds 2,311,230 shares of PETS. The purchase increases the investor’s stake by about 0.12%, indicating incremental but limited additional commitment to the company.